What it sells
Replacing organ transplant with an infusion
Business model breakdown
Buyer: who owns the budget?
UnverifiedHospitals and transplant/hepatology centers and payers that treat end-stage liver failure (inferred; no product price or buyer stated).
Trigger: what makes them buy now?
Shortage of donor organs: the site says only 1 in 33 end-stage patients receive a transplant, about 200,000 develop end-stage liver failure each year.
Workflow: what inputs become what output?
Liver regeneration by infusion of allogeneic stem-cell-derived hepatocytes as an alternative to liver transplant for late-stage liver disease; initial niche indications A1ATD and PKU, then NASH.
Economics: what it saves and how it charges
Pre-revenue therapeutics developer: scalable fully defined manufacturing and an exclusive Stanford license; claims an unlimited cell supply versus donor/cadaver hepatocytes. Funded by investors (Wefunder crowdfunding).
Distribution: how it reaches customers
Allogeneic off-the-shelf cell product intended for on-demand distribution; not yet marketed (pipeline stage), company is raising via Wefunder.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.